Ok. FWIW - I am a senior researcher at a major medical center by profession. I do NIH-funded research studies, including clinical trials. I typically do my own statistical analyses for my studies. I am not a CVD subject matter expert but can certainly interpret results of studies including mechanistic findings. I think the studies of V to date clearly support EPA as the mechanism of action for CV risk reduction, and I do not think the R-It results are invalid. There is no scientific reason why V should not be approved and reimbursed for CV risk reduction here, in Europe, and elsewhere. Economic and political reasons are another matter. Regarding the stock, I am still waiting for the Hail Mary (Denner actions) to be completed.
News 
Market Data 
Discover 
